
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1152840/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects. Endocrine Reviews, 2009, 30, 152-177.	8.9	804
2	Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 379-381.	1.8	587
3	High-Dose Resveratrol Supplementation in Obese Men. Diabetes, 2013, 62, 1186-1195.	0.3	402
4	Weight loss increases circulating levels of ghrelin in human obesity. Clinical Endocrinology, 2002, 56, 203-206.	1.2	393
5	Use of Glucocorticoids and Risk of Venous Thromboembolism. JAMA Internal Medicine, 2013, 173, 743.	2.6	349
6	Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2277-2284.	1.8	324
7	Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2171-2180.	1.8	304
8	Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. Journal of Molecular Endocrinology, 2014, 52, R199-R222.	1.1	282
9	Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 43-51.	1.8	198
10	Epidemiology of Cushing's Syndrome. Neuroendocrinology, 2010, 92, 1-5.	1.2	174
11	Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5627-5631.	1.8	156
12	Insulin-Like Growth Factor (IGF) I, -II, and IGF Binding Protein-3 and Risk of Ischemic Stroke. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5937-5941.	1.8	156
13	Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. European Journal of Endocrinology, 2016, 175, 181-190.	1.9	148
14	Ghrelin Infusion in Humans Induces Acute Insulin Resistance and Lipolysis Independent of Growth Hormone Signaling. Diabetes, 2008, 57, 3205-3210.	0.3	138
15	Fasting Unmasks a Strong Inverse Association between Ghrelin and Cortisol in Serum: Studies in Obese and Normal-Weight Subjects. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 741-746.	1.8	134
16	Detection of growth hormone abuse in sport. Growth Hormone and IGF Research, 2007, 17, 220-226.	0.5	134
17	Effects of Cortisol on Carbohydrate, Lipid, and Protein Metabolism: Studies of Acute Cortisol Withdrawal in Adrenocortical Failure. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3553-3559.	1.8	131
18	Human Growth Hormone Replacement Therapy: Pharmacological and Clinical Aspects. Endocrine Reviews, 1991, 12, 189-207.	8.9	129

#	Article	IF	CITATIONS
19	Mortality in Cushing's syndrome: A systematic review and meta-analysis. European Journal of Internal Medicine, 2012, 23, 278-282.	1.0	127
20	Incidence of craniopharyngioma in Denmark (nÂ=Â189) and estimated world incidence of craniopharyngioma in children and adults. Journal of Neuro-Oncology, 2011, 104, 755-763.	1.4	126
21	Evening <i>Versus </i> Morning Injections of Growth Hormone (GH) in GH-Deficient Patients: Effects on 24-Hour Patterns of Circulating Hormones and Metabolites. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 207-214.	1.8	125
22	Chrelin immunoreactivity in human plasma is suppressed by somatostatin. Clinical Endocrinology, 2002, 57, 539-546.	1.2	125
23	Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 124-133.	1.8	124
24	Long-term growth hormone treatment in growth hormone deficient adults. European Journal of Endocrinology, 1991, 125, 449-453.	1.9	118
25	Hyponatremia and mortality risk: a Danish cohort study of 279 508 acutely hospitalized patients. European Journal of Endocrinology, 2015, 173, 71-81.	1.9	118
26	Expansion of Extracellular Volume and Suppression of Atrial Natriuretic Peptide after Growth Hormone Administration in Normal Man. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 768-772.	1.8	116
27	Plasma ghrelin levels during exercise in healthy subjects and in growth hormone-deficient patients. European Journal of Endocrinology, 2002, 147, 65-70.	1.9	113
28	Growth Hormone (GH) Effects on Bone and Collagen Turnover in Healthy Adults and Its Potential as a Marker of GH Abuse in Sports: A Double Blind, Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1505-1512.	1.8	110
29	Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clinical Endocrinology, 1996, 45, 681-688.	1.2	106
30	Increased Pulsatile, But Not Basal, Growth Hormone Secretion Rates and Plasma Insulin-Like Growth Factor I Levels during the Periovulatory Interval in Normal Women. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1662-1667.	1.8	105
31	Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3644-3652.	1.8	103
32	Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2182-2188.	1.8	98
33	Incidence of GH deficiency – a nationwide study. European Journal of Endocrinology, 2006, 155, 61-71.	1.9	94
34	The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1724-1728.	1.8	94
35	No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1642-1651.	1.8	94
36	Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study. European Journal of Endocrinology, 2017, 176, 1-9.	1.9	91

#	Article	IF	CITATIONS
37	Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated CH secretion in healthy adults. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2209-2215.	1.8	91
38	Hyperthyroidism Is Associated with Suppressed Circulating Ghrelin Levels. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 853-857.	1.8	90
39	Dose-response studies on the metabolic effects of a growth hormone pulse in humans. Metabolism: Clinical and Experimental, 1992, 41, 172-175.	1.5	87
40	Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1829-E1836.	1.8	87
41	Physical exercise increases autophagic signaling through ULK1 in human skeletal muscle. Journal of Applied Physiology, 2015, 118, 971-979.	1.2	87
42	Resveratrol in metabolic health: an overview of the current evidence and perspectives. Annals of the New York Academy of Sciences, 2013, 1290, 74-82.	1.8	85
43	Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3352-3359.	1.8	85
44	Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E920-E927.	1.8	84
45	The Effect of Four Weeks of Supraphysiological Growth Hormone Administration on the Insulin-Like Growth Factor Axis in Women and Men. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4193-4200.	1.8	84
46	Fracture risk is increased in patients with CH deficiency or untreated prolactinomas - a case-control study. Clinical Endocrinology, 2002, 56, 159-167.	1.2	80
47	Acute Effects of Ghrelin Administration on Glucose and Lipid Metabolism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 438-444.	1.8	79
48	Growth Hormone and Glucose Homeostasis. Hormone Research in Paediatrics, 2004, 62, 51-55.	0.8	78
49	Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters. Clinical Endocrinology, 1993, 39, 403-408.	1.2	77
50	Metabolic effects of growth hormone in humans. Metabolism: Clinical and Experimental, 1995, 44, 33-36.	1.5	76
51	Metabolic Effects and Pharmacokinetics of a Growth Hormone Pulse in Healthy Adults: Relation to Age, Sex, and Body Composition. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3612-3618.	1.8	75
52	Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism: Clinical and Experimental, 1992, 41, 728-731.	1.5	73
53	GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E899-E905.	1.8	73
54	Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. Journal of Internal Medicine, 2006, 260, 11-21.	2.7	72

#	Article	IF	CITATIONS
55	Long-Term Effects of Continuous Subcutaneous Infusion <i>Versus</i> Daily Subcutaneous Injections of Growth Hormone (GH) on the Insulin-Like Growth Factor System, Insulin Sensitivity, Body Composition, and Bone and Lipoprotein Metabolism in GH-Deficient Adults <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1222-1228.	1.8	70
56	Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: A double-blind placebo-controlled study. Metabolism: Clinical and Experimental, 1994, 43, 872-877.	1.5	69
57	Fasting, But Not Exercise, Increases Adipose Triglyceride Lipase (ATGL) Protein and Reduces G(0)/G(1) Switch Gene 2 (GOS2) Protein and mRNA Content in Human Adipose Tissue. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1293-E1297.	1.8	68
58	Continuation of Growth Hormone (GH) Therapy in GH-Deficient Patients during Transition from Childhood to Adulthood: Impact on Insulin Sensitivity and Substrate Metabolism. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1912-1917.	1.8	66
59	The Decisive Role of Free Fatty Acids for Protein Conservation during Fasting in Humans with and without Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4371-4378.	1.8	66
60	Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. European Journal of Endocrinology, 2014, 170, 229-236.	1.9	65
61	Effects of Growth Hormone on Glucose and Fat Metabolism in Human Subjects. Endocrinology and Metabolism Clinics of North America, 2007, 36, 75-87.	1.2	63
62	Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men. Prostate, 2015, 75, 1255-1263.	1.2	63
63	Fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling. PLoS ONE, 2014, 9, e102031.	1.1	59
64	Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2216-2224.	1.8	59
65	Growth Hormone Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background, and Growth Hormone Receptor Blockade. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2842-2850.	1.8	58
66	Long-Term Effects of Continuous Subcutaneous Infusion Versus Daily Subcutaneous Injections of Growth Hormone (CH) on the Insulin-Like Growth Factor System, Insulin Sensitivity, Body Composition, and Bone and Lipoprotein Metabolism in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1222-1228.	1.8	58
67	Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E194-E199.	1.8	57
68	Dose Dependency of the Pharmacokinetics and Acute Lipolytic Actions of Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4691-4698.	1.8	56
69	Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2405-2413.	1.8	56
70	Elevated Regional Lipolysis in Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4747-4753.	1.8	55
71	Whole body and forearm substrate metabolism in hyperthyroidism: evidence of increased basal muscle protein breakdown. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E1067-E1073.	1.8	55
72	Hypothesis: Extra-hepatic acromegaly: a new paradigm?. European Journal of Endocrinology, 2011, 164, 11-16.	1.9	55

#	Article	IF	CITATIONS
73	Short-Term Growth Hormone Treatment in Girls With Turner Syndrome Decreases Fat Mass and Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Pediatrics, 2002, 110, 889-896.	1.0	53
74	Muscle mass and function in thyrotoxic patients before and during medical treatment. Clinical Endocrinology, 1999, 51, 693-699.	1.2	52
75	Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary, 2017, 20, 692-701.	1.6	51
76	Insulin Resistance in Patients With Acromegaly. Frontiers in Endocrinology, 2019, 10, 509.	1.5	51
77	Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. European Journal of Endocrinology, 2019, 181, 267-273.	1.9	51
78	Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11β-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1093-1098.	1.8	50
79	Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects. Clinical Endocrinology, 1998, 48, 479-486.	1.2	48
80	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1183-e1194.	1.8	48
81	Effects of Growth Hormone Replacement Therapy on IGF-Related Parameters and on the Pituitary-Gonadal Axis in GH-Deficient Males. Hormone Research in Paediatrics, 1998, 49, 269-278.	0.8	46
82	No Evidence of Insulin-Like Growth Factor-Binding Protein 3 Proteolysis during a Maximal Exercise Test in Elite Athletes1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 669-674.	1.8	46
83	GH Strongly Affects Serum Concentrations of Mannan-Binding Lectin: Evidence for a New IGF-I Independent Immunomodulatory Effect of GH. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5383-5388.	1.8	46
84	Resting metabolic rate in healthy adults: Relation to growth hormone status and leptin levels. Metabolism: Clinical and Experimental, 1998, 47, 1134-1139.	1.5	45
85	Fat Content in Liver and Skeletal Muscle Changes in a Reciprocal Manner in Patients with Acromegaly during Combination Therapy with a Somatostatin Analog and a GH Receptor Antagonist: A Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1227-1235.	1.8	44
86	Effects of growth hormone and insulin-like growth factor-I singly and in combination onin vivocapacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats. Hepatology, 1997, 25, 964-969.	3.6	43
87	Circulating Levels of Ghrelin and GLP-1 are Inversely Related During Glucose Ingestion. Hormone and Metabolic Research, 2002, 34, 411-413.	0.7	43
88	Growth Hormone (GH)-Induced Insulin Resistance Is Rapidly Reversible: An Experimental Study in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2548-2557.	1.8	43
89	Direct Effects of TNF-α on Local Fuel Metabolism and Cytokine Levels in the Placebo-Controlled, Bilaterally Infused Human Leg. Diabetes, 2013, 62, 4023-4029.	0.3	43
90	THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience. European Journal of Endocrinology, 2018, 179, R47-R56.	1.9	43

#	Article	IF	CITATIONS
91	Abdominal Fat Determines Growth Hormone-Binding Protein Levels in Healthy Nonobese Adults <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 123-128.	1.8	42
92	Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor. Clinical Endocrinology, 2000, 52, 181-186.	1.2	42
93	Growth hormone acts along the PPAR <sup>î3</sup> -FSP27 axis to stimulate lipolysis in human adipocytes. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E34-E42.	1.8	42
94	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. European Journal of Endocrinology, 2022, 186, P35-P52.	1.9	42
95	Free fatty acids decrease circulating ghrelin concentrations in humans. European Journal of Endocrinology, 2006, 154, 667-673.	1.9	41
96	Amino acid supplementation is anabolic during the acute phase of endotoxin-induced inflammation: A human randomized crossover trial. Clinical Nutrition, 2016, 35, 322-330.	2.3	40
97	Systemic glucocorticoid use in Denmark: a population-based prevalence study. BMJ Open, 2017, 7, e015237.	0.8	40
98	Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: Dose-response studies with biosynthetic human GH. Calcified Tissue International, 1991, 48, 82-87.	1.5	39
99	Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels. Experimental studies in normal, obese and GH-deficient adults. Growth Hormone and IGF Research, 1999, 9, 52-60.	0.5	39
100	Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 2018, 7, R126-R134.	0.8	39
101	L-Arginine and insulin-tolerance tests in the diagnosis of adult growth hormone deficiency: influence of confounding factors. Clinical Endocrinology, 1998, 48, 109-115.	1.2	38
102	Impact of GHBP interference on estimates of GH and GH pharmacokinetics. Clinical Endocrinology, 2002, 57, 779-786.	1.2	38
103	Gender differences in growth hormone response to exercise before and after rhGH administration and the effect of rhGH on the hormone profile of fit normal adults. Clinical Endocrinology, 2005, 62, 315-322.	1.2	38
104	Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. European Journal of Endocrinology, 2010, 163, 717-726.	1.9	38
105	Differential regulation of lipid and protein metabolism in obese vs. lean subjects before and after a 72-h fast. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E224-E235.	1.8	38
106	Impact of Growth Hormone Receptor Blockade on Substrate Metabolism during Fasting in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4524-4532.	1.8	37
107	Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy. Metabolism: Clinical and Experimental, 1994, 43, 579-583.	1.5	36
108	Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E737-E743.	1.8	36

#	Article	IF	CITATIONS
109	Serum Ghrelin Levels Are Increased in Hypothyroid Patients and Become Normalized by l-Thyroxine Treatment. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2277-2280.	1.8	36
110	Impact of Fasting on Growth Hormone Signaling and Action in Muscle and Fat. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 965-972.	1.8	36
111	Acute Peripheral Metabolic Effects of Intraarterial Chrelin Infusion in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 468-477.	1.8	36
112	Simultaneous determination of β-hydroxybutyrate and β-hydroxy-β-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry. Clinical Biochemistry, 2013, 46, 1877-1883.	0.8	35
113	Gene Expression of a Truncated and the Full-Length Growth Hormone (GH) Receptor in Subcutaneous Fat and Skeletal Muscle in GH-Deficient Adults: Impact of GH Treatment1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 792-796.	1.8	34
114	Growth hormoneâ€induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta Physiologica, 2014, 210, 392-402.	1.8	34
115	Acyl Ghrelin Induces Insulin Resistance Independently of GH, Cortisol, and Free Fatty Acids. Scientific Reports, 2017, 7, 42706.	1.6	34
116	No Evidence of Insulin-Like Growth Factor-Binding Protein 3 Proteolysis during a Maximal Exercise Test in Elite Athletes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 669-674.	1.8	34
117	Acute exposure to GH during exercise stimulates the turnover of free fatty acids in GH-deficient men. Journal of Applied Physiology, 2004, 96, 747-753.	1.2	33
118	Gene Transcription of Receptors for Growth Hormone-Releasing Peptide and Somatostatin in Human Pituitary Adenomas1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2997-3000.	1.8	32
119	The effect of the deterioration of insulin sensitivity onβ-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy. Growth Hormone and IGF Research, 1999, 9, 96-105.	0.5	32
120	Abdominal Fat Determines Growth Hormone-Binding Protein Levels in Healthy Nonobese Adults. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 123-128.	1.8	32
121	Continuation of Growth Hormone (GH) Substitution during Fasting in GH-Deficient Patients Decreases Urea Excretion and Conserves Protein Synthesis1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3120-3129.	1.8	31
122	Growth Hormone Treatment in Adults with Adult-Onset Growth Hormone Deficiency Increases Iliac Crest Trabecular Bone Turnover: A 1-Year, Double-Blind, Randomized, Placebo-Controlled Study. Journal of Bone and Mineral Research, 2010, 15, 293-300.	3.1	31
123	Prolactinoma-associated headache and dopamine agonist treatment. Cephalalgia, 2014, 34, 493-502.	1.8	31
124	Growth hormone controls lipolysis by regulation of FSP27 expression. Journal of Endocrinology, 2018, 239, 289-301.	1.2	31
125	The Effect of Growth Hormone on the Insulin-Like Growth Factor System during Fasting. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3292-3298.	1.8	30
126	Ectopic ACTH Syndrome: Discrepancy between Somatostatin Receptor Status in vivo and ex vivo, and between Immunostaining and Gene Transcription for POMC and CRH. Hormone Research in Paediatrics, 2002, 57, 200-204.	0.8	29

#	Article	IF	CITATIONS
127	Calorigenic effects of growth hormone: the role of thyroid hormones. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1416-1419.	1.8	29
128	Gene Expression of a Truncated and the Full-Length Growth Hormone (GH) Receptor in Subcutaneous Fat and Skeletal Muscle in GH-Deficient Adults: Impact of GH Treatment. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 792-796.	1.8	29
129	Growth hormone prevents prednisolone-induced increase in functional hepatic nitrogen clearance in normal man. Journal of Hepatology, 1997, 27, 789-795.	1.8	28
130	Gene expression of the GH receptor in subcutaneous and intraabdominal fat in healthy females: relationship to GH-binding protein. European Journal of Endocrinology, 2004, 150, 773-777.	1.9	28
131	Whole body metabolic effects of prolonged endurance training in combination with erythropoietin treatment in humans: a randomized placebo controlled trial. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E879-E889.	1.8	28
132	Sustained AS160 and TBC1D1 phosphorylations in human skeletal muscle 30 min after a single bout of exercise. Journal of Applied Physiology, 2014, 117, 289-296.	1.2	28
133	Continuation of Growth Hormone (GH) Therapy in GH-Deficient Patients during Transition from Childhood to Adulthood: Impact on Insulin Sensitivity and Substrate Metabolism. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1912-1917.	1.8	28
134	Differential effects of growth hormone and prednisolone on energy metabolism and leptin levels in humans. Metabolism: Clinical and Experimental, 1998, 47, 83-88.	1.5	27
135	Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults. Clinical Endocrinology, 1999, 51, 309-316.	1.2	27
136	Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. European Journal of Endocrinology, 2005, 152, 77-85.	1.9	27
137	Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clinical Endocrinology, 2007, 66, 426-433.	1.2	27
138	Impact of GH substitution on exercise capacity and muscle strength in GHâ€deficient adults: a metaâ€analysis of blinded, placeboâ€controlled trials. Clinical Endocrinology, 2009, 71, 860-866.	1.2	27
139	Reduced mRNA and Protein Expression of Perilipin A and G0/G1 Switch Gene 2 (G0S2) in Human Adipose Tissue in Poorly Controlled Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1348-E1352.	1.8	27
140	Glucose and Fat Metabolism in Acromegaly: From Mice Models to Patient Care. Neuroendocrinology, 2016, 103, 96-105.	1.2	27
141	Body fluids, circadian blood pressure and plasma renin during growth hormone administration: a placebo-controlled study with two growth hormone doses in healthy adults. Scandinavian Journal of Clinical and Laboratory Investigation, 1995, 55, 663-669.	0.6	26
142	Effects of free fatty acids, growth hormone and growth hormone receptor blockade on serum ghrelin levels in humans. Clinical Endocrinology, 2007, 66, 641-645.	1.2	26
143	Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men. Journal of Functional Foods, 2014, 6, 305-310.	1.6	26
144	Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials. Growth Hormone and IGF Research, 2017, 34, 38-44.	0.5	26

#	Article	IF	CITATIONS
145	Long-term effects of growth hormone (GH) on body fluid distribution in GH deficient adults: a four months double blind placebo controlled trial. European Journal of Endocrinology, 1999, 140, 11-16.	1.9	25
146	Modulation of basal glucose metabolism and insulin sensitivity by growth hormone and free fatty acids during short-term fasting. European Journal of Endocrinology, 2004, 150, 779-787.	1.9	25
147	Exercise and Fasting Activate Growth Hormone-Dependent Myocellular Signal Transducer and Activator of Transcription-5b Phosphorylation and Insulin-Like Growth Factor-I Messenger Ribonucleic Acid Expression in Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E64-E68.	1.8	25
148	Insulin and GH Signaling in Human Skeletal Muscle In Vivo following Exogenous GH Exposure: Impact of an Oral Glucose Load. PLoS ONE, 2011, 6, e19392.	1.1	25
149	Molecular adaptations in human subcutaneous adipose tissue after ten weeks of endurance exercise training in healthy males. Journal of Applied Physiology, 2019, 126, 569-577.	1.2	25
150	Growth Hormone and Obesity. Endocrinology and Metabolism Clinics of North America, 2020, 49, 239-250.	1.2	25
151	Gene Transcription of Receptors for Growth Hormone-Releasing Peptide and Somatostatin in Human Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2997-3000.	1.8	25
152	Continuation of Growth Hormone (GH) Substitution during Fasting in GH-Deficient Patients Decreases Urea Excretion and Conserves Protein Synthesis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3120-3129.	1.8	25
153	Hyperthyroidism and cation pumps in human skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E1265-E1269.	1.8	24
154	Cardiovascular effects of intravenous ghrelin infusion in healthy young men. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3020-H3026.	1.5	24
155	Novel serum biomarkers for erythropoietin use in humans: a proteomic approach. Journal of Applied Physiology, 2011, 110, 149-156.	1.2	24
156	Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: a randomized trial. European Journal of Endocrinology, 2011, 165, 293-300.	1.9	23
157	Acute presentation of craniopharyngioma in children and adults in a Danish national cohort. Pituitary, 2013, 16, 528-535.	1.6	23
158	Acute peripheral tissue effects of ghrelin on interstitial levels of glucose, glycerol, and lactate: a microdialysis study in healthy human subjects. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E1273-E1280.	1.8	23
159	Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. European Journal of Endocrinology, 2015, 173, 269-273.	1.9	23
160	Long-term efficacy and tolerability of octreotide treatment in acromegaly. Metabolism: Clinical and Experimental, 1992, 41, 44-50.	1.5	22
161	Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency. Clinical Endocrinology, 2000, 52, 25.	1.2	22
162	Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis. European Journal of Endocrinology, 2005, 153, 545-549.	1.9	22

#	Article	IF	CITATIONS
163	Thyroid hormone increases mannan-binding lectin levels. European Journal of Endocrinology, 2005, 153, 643-649.	1.9	22
164	Effects of GH in human muscle and fat. Pediatric Nephrology, 2010, 25, 705-709.	0.9	22
165	Gene expression in skeletal muscle after an acute intravenous GH bolus in human subjects: identification of a mechanism regulating ANGPTL4. Journal of Lipid Research, 2013, 54, 1988-1997.	2.0	22
166	Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities. European Journal of Endocrinology, 2014, 170, 39-48.	1.9	22
167	Circulating acylghrelin levels are suppressed by insulin and increase in response to hypoglycemia in healthy adult volunteers. European Journal of Endocrinology, 2015, 172, 357-362.	1.9	22
168	Substrate Metabolism and Insulin Sensitivity During Fasting in Obese Human Subjects: Impact of GH Blockade. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1340-1349.	1.8	22
169	Prolonged fasting-induced metabolic signatures in human skeletal muscle of lean and obese men. PLoS ONE, 2018, 13, e0200817.	1.1	22
170	Growth Hormone Increases Vascular Cell Adhesion Molecule 1 Expression:in Vivoandin VitroEvidence. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 909-916.	1.8	21
171	Sex Steroids and the Growth Hormone/Insulin-Like Growth Factor-I Axis in Adults. Hormone Research in Paediatrics, 2005, 64, 37-40.	0.8	21
172	The effect of submaximal exercise on immuno- and bioassayable IGF-I activity in patients with GH-deficiency and healthy subjects. Growth Hormone and IGF Research, 2005, 15, 283-290.	0.5	21
173	Free Fatty Acids Inhibit Growth Hormone/Signal Transducer and Activator of Transcription-5 Signaling in Human Muscle: A Potential Feedback Mechanism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2204-2207.	1.8	21
174	Local administration of growth hormone stimulates tendon collagen synthesis in elderly men. Journal of Applied Physiology, 2012, 113, 1432-1438.	1.2	21
175	DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. European Journal of Endocrinology, 2016, 175, R247-R253.	1.9	21
176	Sex differences in acromegaly at diagnosis: A nationwide cohort study and metaâ€analysis of the literature. Clinical Endocrinology, 2021, 94, 625-635.	1.2	21
177	Body Composition and Circulating Levels of Insulin, Insulin-Like Growth Factor-Binding Protein-1 and Growth Hormone (GH)-Binding Protein Affect the Pharmacokinetics of GH in Adults Independently of Age. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2185-2193.	1.8	20
178	Dose–response effects of free fatty acids on amino acid metabolism and ureagenesis. Acta Physiologica, 2008, 192, 369-379.	1.8	20
179	Identification of New Biomarkers of Low-Dose GH Replacement Therapy in GH-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2089-2097.	1.8	20
180	Growth Hormone (GH)-Deficiency in Adults: Clinical Features and Effects of GH Substitution. Journal of Pediatric Endocrinology and Metabolism, 1994, 7, 283-93.	0.4	19

#	Article	IF	CITATIONS
181	Lack of Observed Association between High Plasma Osteoprotegerin Concentrations and Ischemic Stroke Risk in a Healthy Population. Clinical Chemistry, 2008, 54, 1969-1974.	1.5	19
182	Increased Protein Turnover and Proteolysis Is an Early and Primary Feature of Short-Term Experimental Hyperthyroidism in Healthy Women. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3999-4005.	1.8	19
183	Decreased Lipid Intermediate Levels and Lipid Oxidation Rates Despite Normal Lipolysis in Patients with Hypothyroidism. Thyroid, 2010, 20, 843-849.	2.4	19
184	Acromegaly according to the Danish National Registry of Patients: how valid are ICD diagnoses and how do patterns of registration affect the accuracy of registry data?. Clinical Epidemiology, 2014, 6, 295.	1.5	19
185	Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GHâ€deficient patients. Clinical Endocrinology, 1996, 45, 333-339.	1.2	18
186	Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women. Clinical Endocrinology, 2000, 52, 305-312.	1.2	18
187	Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. European Journal of Endocrinology, 2018, 178, 65-74.	1.9	18
188	Fuel metabolism in growth hormone-deficient adults. Metabolism: Clinical and Experimental, 1995, 44, 103-107.	1.5	17
189	Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients. Metabolism: Clinical and Experimental, 1995, 44, 6-14.	1.5	17
190	Effects of long-term growth hormone (GH) and triiodothyronine (T3) administration on functional hepatic nitrogen clearance in normal man. Journal of Hepatology, 1996, 24, 313-319.	1.8	17
191	Growth Hormone Therapy in Adults. Frontiers in Neuroendocrinology, 2001, 22, 213-246.	2.5	17
192	Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men. Journal of Applied Physiology, 2012, 112, 1114-1121.	1.2	17
193	Direct Effects of Locally Administered Lipopolysaccharide on Glucose, Lipid, and Protein Metabolism in the Placebo-Controlled, Bilaterally Infused Human Leg. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2090-2099.	1.8	17
194	Validity of the International Classification of Diseases, 10th revision discharge diagnosis codes for hyponatraemia in the Danish National Registry of Patients. BMJ Open, 2014, 4, e004956.	0.8	17
195	Kinetics and utilization of lipid sources during acute exercise and acipimox. American Journal of Physiology - Endocrinology and Metabolism, 2014, 307, E199-E208.	1.8	17
196	The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. Growth Hormone and IGF Research, 2015, 25, 174-181.	0.5	17
197	Temporal patterns of lipolytic regulators in adipose tissue after acute growth hormone exposure in human subjects: A randomized controlled crossover trial. Molecular Metabolism, 2019, 29, 65-75.	3.0	17
198	Clinical indicators of adrenal insufficiency following discontinuation of oral glucocorticoid therapy: A Danish population-based self-controlled case series analysis. PLoS ONE, 2019, 14, e0212259.	1.1	17

#	Article	IF	CITATIONS
199	Effects of growth hormone (CH) administration on functional hepatic nitrogen clearance: studies in normal subjects and CH-deficient patients. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 1220-1224.	1.8	17
200	Effects of leptin on basal and FSH stimulated steroidogenesis in human granulosa luteal cells. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 931-935.	1.3	16
201	Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. European Journal of Endocrinology, 2005, 152, 719-726.	1.9	16
202	GH signaling in human adipose and muscle tissue during â€~feast and famine': amplification of exercise stimulation following fasting compared to glucose administration. European Journal of Endocrinology, 2015, 173, 283-290.	1.9	16
203	Effects of Prednisolone on Serum and Tissue Fluid IGF-I Receptor Activation and Post-Receptor Signaling in Humans. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4031-4040.	1.8	16
204	Growth hormone (GH) therapy in GH-deficient patients, the plasma Factor VIII-von Willebrand factor complex, and capillary fragility. A double-blind, placebo-controlled crossover study. Scandinavian Journal of Clinical and Laboratory Investigation, 1990, 50, 417-420.	0.6	15
205	Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients. Growth Hormone and IGF Research, 2002, 12, 425-433.	0.5	15
206	Serum Insulin-Like Growth Factor I Levels in Growth Hormone-Deficient Adults: Influence of Sex Steroids. Hormone Research in Paediatrics, 2004, 62, 73-76.	0.8	15
207	Time-course effects of physiological free fatty acid surges on insulin sensitivity in humans. Acta Physiologica, 2011, 201, 349-356.	1.8	15
208	Heart Valve Disease among Patients with Hyperprolactinemia: A Nationwide Population-Based Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1629-1634.	1.8	15
209	Growth Hormone Signaling in Muscle and Adipose Tissue of Obese Human Subjects: Associations With Measures of Body Composition and Interaction With Resveratrol Treatment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2565-E2573.	1.8	15
210	Growth hormone (GH) substitution for one year normalizes elevated GH-binding protein levels in GH-deficient adults secondary to a reduction in body fat. A placebo-controlled trial. Growth Hormone and IGF Research, 1998, 8, 105-112.	0.5	14
211	Concomitant, specific determination of growth hormone and pegvisomant in human serum. Growth Hormone and IGF Research, 2007, 17, 431-434.	0.5	14
212	Evaluation of Functional Erythropoietin Receptor Status in Skeletal Muscle In Vivo: Acute and Prolonged Studies in Healthy Human Subjects. PLoS ONE, 2012, 7, e31857.	1.1	14
213	Hormone and Cytokine Responses to Repeated Endotoxin Exposures—No Evidence of Endotoxin Tolerance After 5 Weeks in Humans. Shock, 2015, 44, 32-35.	1.0	14
214	Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients. Hormone and Metabolic Research, 2019, 51, 62-68.	0.7	14
215	Stimulation of the 150-Kilodalton Insulin-Like Growth Factor-Binding Protein-3 Ternary Complex by Continuous and Pulsatile Patterns of Growth Hormone (GH) Administration in GH-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4310-4314.	1.8	14
216	Reversible insulin resistance in muscle and fat unrelated to the metabolic syndrome in patients with acromegaly. EBioMedicine, 2022, 75, 103763.	2.7	14

#	Article	IF	CITATIONS
217	GH stimulation tests: evaluation of GH responses to heat test versus insulin-tolerance test. European Journal of Endocrinology, 1998, 139, 605-610.	1.9	13
218	Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects. Proteomics, 2011, 11, 3565-3571.	1.3	13
219	Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. Clinical Endocrinology, 2014, 80, 92-100.	1.2	13
220	Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients. Growth Hormone and IGF Research, 1999, 9, 451-457.	0.5	12
221	The growth hormone (GH)– insulin-like growth factor axis during testosterone replacement therapy in CH-treated hypopituitary males. Growth Hormone and IGF Research, 2001, 11, 104-109.	0.5	12
222	Evaluation of growth hormone stimulation tests in cured acromegalic patients. Growth Hormone and IGF Research, 2003, 13, 347-352.	0.5	12
223	Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters. Clinical Endocrinology, 2004, 60, 461-469.	1.2	12
224	The management of adult growth hormone deficiency syndrome. Expert Opinion on Pharmacotherapy, 2008, 9, 2435-2450.	0.9	12
225	Cushing's syndrome in children and adolescents: a Danish nationwide population-based cohort study. European Journal of Endocrinology, 2017, 176, 567-574.	1.9	12
226	Growth hormone signaling and action in obese versus lean human subjects. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E333-E344.	1.8	12
227	A multidimensional cohort study of late toxicity after intensity modulated radiotherapy for sinonasal cancer. Radiotherapy and Oncology, 2020, 151, 58-65.	0.3	12
228	Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals. Metabolism: Clinical and Experimental, 2020, 105, 154188.	1.5	12
229	Substrate metabolism during modest hyperinsulinemia in response to isolated hyperketonemia in in insulin-dependent diabetic subjects. Metabolism: Clinical and Experimental, 1990, 39, 1309-1313.	1.5	11
230	Different Effects of Continuous and Intermittent Patterns of Growth Hormone Administration on Lipoprotein Levels inGrowth Hormone-Deficient Patients. Hormone Research in Paediatrics, 1998, 50, 284-291.	0.8	11
231	Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2975-2982.	1.8	11
232	The acute effects of growth hormone in adipose tissue is associated with suppression of antilipolytic signals. Physiological Reports, 2020, 8, e14373.	0.7	11
233	L-arginine-induced growth hormone secretion is not influenced by co-infusion of the nitric oxide synthase inhibitor N-monomethyl- L-arginine in healthy men. Growth Hormone and IGF Research, 1999, 9, 69-73.	0.5	10
234	Serum ghrelin levels are suppressed in hypopituitary patients following insulin-induced hypoglycaemia irrespective of GH status. Clinical Endocrinology, 2006, 65, 210-214.	1.2	10

#	Article	IF	CITATIONS
235	Redundancy in regulation of lipid accumulation in skeletal muscle during prolonged fasting in obese men. Physiological Reports, 2019, 7, e14285.	0.7	10
236	Fibroblast Activation Protein is a GH Target: A Prospective Study of Patients with Acromegaly Before and After Treatment. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 106-115.	1.8	10
237	Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals. Diabetologia, 2020, 63, 2641-2653.	2.9	10
238	Soluble Klotho: a possible predictor of quality of life in acromegaly patients. Endocrine, 2020, 69, 165-174.	1.1	10
239	Effects of growth hormone on serum lipids and lipoproteins: Possible significance of increased peripheral conversion of thyroxine to triiodothyronine. Metabolism: Clinical and Experimental, 1996, 45, 1016-1020.	1.5	9
240	Hepatic amino- to urea-N clearance and forearm amino-N exchange during hypoglycemic and euglycemic hyperinsulinemia in normal man. Journal of Hepatology, 1999, 30, 819-825.	1.8	9
241	Somatropin and Glucose Homeostasis. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2002, 1, 229-234.	1.8	9
242	Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3716-3723.	1.8	9
243	Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes. Clinical Endocrinology, 2016, 85, 202-206.	1.2	9
244	Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study. Acta Oncológica, 2018, 57, 522-527.	0.8	9
245	Effects of short-term prednisolone treatment on indices of lipolysis and lipase signaling in abdominal adipose tissue in healthy humans. Metabolism: Clinical and Experimental, 2019, 99, 1-10.	1.5	9
246	An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140105.	0.2	9
247	Hepatic amino nitrogen conversion and organ N-contents in hypothyroidism, with thyroxine replacement, and in hypethyroid rats. Journal of Hepatology, 1997, 26, 409-416.	1.8	8
248	Peroxisome proliferatorâ€activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. Clinical Endocrinology, 2008, 69, 452-461.	1.2	8
249	Reduced Expression of Uncoupling Protein 2 in Adipose Tissue in Patients with Hypothyroidism. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3537-3541.	1.8	8
250	Ten weeks of aerobic training does not result in persistent changes in VLDL triglyceride turnover or oxidation in healthy men. European Journal of Endocrinology, 2014, 171, 603-613.	1.9	8
251	GH signaling in skeletal muscle and adipose tissue in healthy human subjects: impact of gender and age. European Journal of Endocrinology, 2014, 171, 623-631.	1.9	8
252	Prolonged erythropoietin treatment does not impact gene expression in human skeletal muscle. Muscle and Nerve, 2015, 51, 554-561.	1.0	8

#	Article	IF	CITATIONS
253	Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 266-275.	1.8	8
254	Growth hormone replacement in adults: Real-world data from two large studies in US and Europe. Growth Hormone and IGF Research, 2020, 50, 71-82.	0.5	8
255	Glucocorticoid use and risk of suicide: a Danish populationâ€based caseâ€control study. World Psychiatry, 2021, 20, 142-143.	4.8	8
256	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. Endocrine Practice, 2021, 27, 1216-1224.	1.1	8
257	The Socioeconomic Consequences of Cushing's Syndrome: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2921-e2929.	1.8	8
258	Serum growth hormone (GH) profiles after nasally administered GH in normal subjects and GH deficient patients. Clinical Endocrinology, 1994, 40, 511-513.	1.2	7
259	Expression of Leptin Receptor Isoforms and Effects of Leptin on the Proliferation and Hormonal Secretion in Human Pituitary Adenomas. Hormone Research in Paediatrics, 2004, 62, 129-136.	0.8	7
260	Acute Peripheral Metabolic Effects of Intraarterial Leg Infusion of Somatostatin in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2581-2589.	1.8	7
261	Acute intravenous acyl ghrelin infusion induces thirst but does not affect sodium excretion: two randomized, double-blind, placebo-controlled crossover studies in hypopituitary patients. European Journal of Endocrinology, 2019, 181, 23-30.	1.9	7
262	Should patients with adult GH deficiency receive GH replacement?. European Journal of Endocrinology, 2022, 186, D1-D15.	1.9	7
263	Bioavailability of Recombinant Human Growth Hormone in Different Concentrations and Formulations. Basic and Clinical Pharmacology and Toxicology, 1996, 79, 144-149.	0.0	6
264	Safety aspects of growth hormone replacement in adults. Growth Hormone and IGF Research, 2001, 11, 59-71.	0.5	6
265	Serum Proteomic Changes after Randomized Prolonged Erythropoietin Treatment and/or Endurance Training: Detection of Novel Biomarkers. PLoS ONE, 2015, 10, e0117119.	1.1	6
266	Intact Pituitary Function is Decisive for the Catabolic Response to TNF-α: Studies of Protein, Glucose and Fatty Acid Metabolism in Hypopituitary and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 578-586.	1.8	6
267	Stress hormone release is a key component of the metabolic response to lipopolysaccharide: studies in hypopituitary and healthy subjects. European Journal of Endocrinology, 2016, 175, 455-465.	1.9	6
268	Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. Endocrine, 2017, 56, 589-594.	1.1	6
269	Shortâ€ŧerm acipimox treatment is associated with decreased cardiac parasympathetic modulation. British Journal of Clinical Pharmacology, 2017, 83, 2671-2677.	1.1	6
270	Prevalence of lifestyle characteristics in glucocorticoid users and non-users: a Danish population-based cross-sectional study. BMJ Open, 2019, 9, e030780.	0.8	6

#	Article	IF	CITATIONS
271	Sex difference in patients with controlled acromegaly—A multicentre survey. Clinical Endocrinology, 2023, 98, 74-81.	1.2	6
272	Clinical Aspects of Growth Hormone Deficiency in Adults. , 2005, 33, 1-20.		5
273	Peroxisome proliferatorâ€activated receptor γ (PPAR) agonism reduces the insulinâ€stimulated increase in circulating interleukinâ€6 in GH replaced GHâ€deficient adults. Clinical Endocrinology, 2009, 71, 363-368.	1.2	5
274	Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo. Lipids in Health and Disease, 2016, 15, 160.	1.2	5
275	A Simple Twist of Science: the Convoluted Tale of Ghrelin Continues. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3279-3280.	1.8	4
276	Ghrelin- and GH-induced insulin resistance: no association with retinol-binding protein-4. Endocrine Connections, 2013, 2, 96-103.	0.8	4
277	β-Lactoglobulin Is Insulinotropic Compared with Casein and Whey Protein Ingestion during Catabolic Conditions in Men in a Double-Blinded Randomized Crossover Trial. Journal of Nutrition, 2021, 151, 1462-1472.	1.3	4
278	A model mimicking catabolic inflammatory disease; a controlled randomized study in humans. PLoS ONE, 2020, 15, e0241274.	1.1	4
279	Prenatal exposure to glucocorticoids and the prevalence of overweight or obesity in childhood. European Journal of Endocrinology, 2022, , .	1.9	4
280	In utero exposure to glucocorticoids and risk of anxiety and depression in childhood or adolescence. Psychoneuroendocrinology, 2022, 141, 105766.	1.3	4
281	Growth hormone receptor expression and function in pituitary adenomas. Clinical Endocrinology, 2004, 60, 576-583.	1.2	3
282	Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution. Clinical Epidemiology, 2017, Volume 9, 591-600.	1.5	3
283	Risk of cancer in patients with thyroid disease and venous thromboembolism. Clinical Epidemiology, 2018, Volume 10, 907-915.	1.5	3
284	Unacylated Ghrelin Does Not Acutely Affect Substrate Metabolism or Insulin Sensitivity in Men With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2435-2442.	1.8	3
285	Increased lipolysis after infusion of acylated ghrelin: a randomized, doubleâ€blinded placeboâ€controlled trial in hypopituitary patients. Clinical Endocrinology, 2020, 93, 672-677.	1.2	3
286	Phenotypic and genotypic features of a large kindred with a germline AIP variant. Clinical Endocrinology, 2020, 93, 146-153.	1.2	3
287	Continuation of growth hormone therapy versus placebo in transition-phase patients with growth hormone deficiency: impact on body composition, insulin sensitivity, and thyroid function. Journal of Pediatric Endocrinology and Metabolism, 2002, 15 Suppl 5, 1355-60.	0.4	3
288	Growth hormone treatment in adults:Is there a true gender difference?. Growth Hormone and IGF Research, 2001, 11, S43-S48.	0.5	2

#	Article	IF	CITATIONS
289	Biochemical definitions of disease activity in acromegaly. Growth Hormone and IGF Research, 2003, 13, 98-103.	0.5	2
290	Assessment of hydration by means of bioelectrical impedance and arm muscle area during growth hormone (GH) replacement therapy: A prospective study of 130 GH-deficient patients. Growth Hormone and IGF Research, 2007, 17, 227-233.	0.5	2
291	Systemic, but not local, low-grade endotoxinemia increases plasma sCD163 independently of the cortisol response. Endocrine Connections, 2019, 8, 95-99.	0.8	2
292	No Influence of Prednisolone on IGFBP-3 Proteolysis in Healthy Young Men. Hormone Research in Paediatrics, 2001, 55, 95-101.	0.8	1
293	Giant prolactinoma presenting as a skull base tumor with erosion of the cervical vertebrae: pronounced responsiveness to dopamine agonist treatment. British Journal of Neurosurgery, 2015, 29, 87-89.	0.4	1
294	No effect of 10 weeks erythropoietin treatment on lipid oxidation in healthy men. Endocrine Connections, 2020, 9, 1148-1155.	0.8	1
295	Growth Hormone. Principles of Medical Biology, 1997, 10, 451-466.	0.1	0
296	Role of ghrelin in growth hormone-deficient patients. Expert Review of Endocrinology and Metabolism, 2006, 1, 343-351.	1.2	0
297	Growth Hormone (GH) Treatment in GH-Deficient Adults; Therapeutic and Diagnostic Aspects. Clinical Pediatric Endocrinology, 1994, 3, 63-71.	0.4	0
298	Response to the Letter by Lindholm, et al. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L66-L67.	1.8	0